Engrail Therapeutics

aid: engrail-therapeutics
name: Engrail Therapeutics
description: Engrail Therapeutics is a clinical-stage precision-neuroscience pharmaceutical company founded in 2019 and headquartered
  in San Diego, California. It applies precision chemistry and pharmacology to scientifically validated mechanisms of action,
  developing targeted small-molecule therapies for neuropsychiatric and neurodevelopmental diseases with significant unmet
  need — including generalized anxiety disorder, major depressive disorder characterized by anhedonia, post-traumatic stress
  disorder and rare neurodegenerative conditions. Its lead program, ENX-102, is a highly selective GABA-A alpha-2,3,5 positive
  allosteric modulator in Phase 2 (the ENCALM trial) for generalized anxiety disorder; ENX-104 is in clinical development
  for anhedonic depression. The company closed an oversubscribed $157M Series B in March 2024 co-led by F-Prime Capital, Forbion
  and Norwest Venture Partners, bringing total capital raised since inception past $220M. Engrail publishes no product or
  developer API; the machine-readable surfaces catalogued here are the public read-only content API and the OAuth-protected
  Model Context Protocol servers exposed by its corporate website.
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: true
  label: Hosted service · you call their endpoint
  confidence: high
  source:
  - openapi
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: self-serve
  trial: false
  try_now: false
  public: false
  label: Self-serve signup
  confidence: medium
  source:
  - authentication
  - scopes
  - security
  generated: '2026-09-02'
  method: derived
image: https://www.engrail.com/wp-content/uploads/2022/05/logo.png
url: https://raw.githubusercontent.com/api-evangelist/engrail-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pipeline
specificationVersion: '0.23'
created: '2026-08-01'
modified: '2026-08-01'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Neuroscience
- Clinical Trials
- Drug Development
- Healthcare
- Mental Health
- MCP
tags_raw:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Neuroscience
- Clinical Trials
- Drug Development
- Healthcare
- Mental Health
- Model Context Protocol
apis:
- aid: engrail-therapeutics:mcp
  name: Engrail Therapeutics MCP Servers
  description: Two live Model Context Protocol servers registered under the `mcp` REST namespace on engrail.com, fronted by
    RFC 8414 and RFC 9728 OAuth discovery documents at the apex. Both are OAuth-protected — anonymous tools/list returns HTTP
    401 — so the live tool manifest is not readable and no tool list is recorded.
  humanURL: https://www.engrail.com/
  baseURL: https://www.engrail.com/wp-json/mcp/mcp-oauth-server
  tags:
  - MCP
  - Agents
  tags_raw:
  - Model Context Protocol
  - Agents
  properties:
  - type: MCPServer
    url: mcp/engrail-therapeutics-mcp.yml
  - type: ToolCrosswalk
    url: mcp/engrail-therapeutics-tool-crosswalk.yml
  x-surface: platform-generated
  x-platform: wordpress
  x-platform-surface: mcp-plugin
- aid: engrail-therapeutics:engrail-com-website-wordpress-rest
  name: Engrail Therapeutics Website (WordPress REST)
  description: 'The public WordPress REST API (wp-json) of the Engrail Therapeutics website at www.engrail.com: the route
    index of the site''s content management system, catalogued as one site surface rather than as separate APIs.'
  baseURL: https://www.engrail.com/wp-json
  tags:
  - WordPress
  x-surface: platform-generated
  properties:
  - type: Documentation
    url: https://www.engrail.com/wp-json
  x-platform: wordpress
  x-platform-surface: rest
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Overlay
  url: overlays/engrail-therapeutics-content-overlay.yaml
- type: Website
  url: https://www.engrail.com/
- type: SecondaryMarket
  url: https://forgeglobal.com/engrail-therapeutics_stock/
- type: About
  url: https://www.engrail.com/about-us/
- type: Blog
  url: https://www.engrail.com/investors-media/
- type: BlogRSS
  url: https://www.engrail.com/feed/
- type: Support
  url: https://www.engrail.com/contact-us/
- type: TermsOfService
  url: https://www.engrail.com/terms-of-use/
- type: PrivacyPolicy
  url: https://www.engrail.com/privacy-policy/
- type: LegalDisclaimer
  url: https://www.engrail.com/legal-disclaimer/
- type: Careers
  url: https://www.engrail.com/careers/
- type: Partners
  url: https://www.engrail.com/partners/
- type: Pipeline
  url: https://www.engrail.com/pipeline/
- type: LinkedIn
  url: https://www.linkedin.com/company/engrail-therapeutics
- type: WellKnown
  url: well-known/engrail-therapeutics-well-known.yml
- type: Authentication
  url: authentication/engrail-therapeutics-authentication.yml
- type: OAuthScopes
  url: scopes/engrail-therapeutics-scopes.yml
- type: Conventions
  url: conventions/engrail-therapeutics-conventions.yml
- type: Conformance
  url: conformance/engrail-therapeutics-conformance.yml
- type: Lifecycle
  url: lifecycle/engrail-therapeutics-lifecycle.yml
- type: DomainSecurity
  url: security/engrail-therapeutics-domain-security.yml
- type: LLMsTxt
  url: llms/engrail-therapeutics-llms.txt
- type: AgentSkill
  url: skills/_index.yml
- type: ErrorCatalog
  url: errors/engrail-therapeutics-problem-types.yml
- type: DataModel
  url: data-model/engrail-therapeutics-data-model.yml
x-enrichment:
  date: '2026-08-01'
  status: enriched
  artifacts_added: 20
  pass: local-v1